Biocon Share Price Target 2024, 2025, 2030, 2050

WhatsApp Channel Join Now
Telegram Channel Join Now

Biocon Limited, established in 1978, is a renowned Indian biopharmaceutical business that has advanced globally. One of India’s leading biotechnology companies, Biocon develops and manufactures biosimilars, innovative biologics, and complicated small molecule APIs.

Innovation and affordability in healthcare have made the firm a biopharmaceutical leader.

What is Biocon Industries Ltd NSE: BIOCON?

Bangalore-based Biocon Industries Ltd (NSE: BIOCON) is a significant biopharmaceutical firm. The business does cutting-edge diabetes, cancer, and immunology research. Biocon’s business approach includes biosimilar, new biologic, and branded formulation development. Biocon is a biotechnology powerhouse with a worldwide presence and strategic agreements with major pharmaceutical corporations.

Fundamental Table

MetricValue
Market Cap₹437.60B
P/E Ratio27.68
Dividend Yield0.14%
52-Week High₹395.80
52-Week Low₹217.50

Key Metrics Table

MetricValue
Revenue (TTM)₹34.33B
Net Income (TTM)₹6.60B
EPS (TTM)₹5.31
EBITDA₹5.96B
Debt to EquityNot available

Peers & Comparison Table

CompanyMarket Cap (₹B)P/E Ratio
Biocon437.6027.68
Dr. Reddy’s873.4928.75
Sun Pharma2,549.2636.81
Cipla938.9933.24
Lupin466.9142.17

Biocon Share Price Target Tomorrow

Price TypeMinimumMaximum
Tomororw-7.95+7.80

Biocon Share Price Target 2024

Biocon is a prominent biopharmaceutical brand that researches, develops, and manufactures biosimilars and new biologics. It creates and tests its items internally. Its diverse product line strengthens its market position. Biocon employs nearly 16,000 people using cutting-edge technologies. It aspires to develop inexpensive, high-quality biopharmaceuticals on schedule. For 2024, the price goal is ₹450. Our study predicts a price range of ₹250 to ₹450.

YearMinimum Price (₹)Maximum Price (₹)
2024250450
MonthMinimum Price (₹)Maximum Price (₹)
January250300
February250300
March240290
April250320
May280330
June270360
July320390
August320390
September340420
October320430
November330450
December300450

Biocon Share Price Target 2025

Biocon strengthens its biopharmaceutical market position. Expanding their biosimilar portfolio and entering new areas could boost revenue. Strategic collaborations and R&D expenditures should benefit the organization. Their production capabilities are developing to satisfy demand. For 2025, the price objective is ₹530. Our study predicts a price range of ₹300 to ₹530.

YearMinimum Price (₹)Maximum Price (₹)
2025300530
MonthMinimum Price (₹)Maximum Price (₹)
January300460
February320470
March330480
April350485
May320490
June310495
July340500
August370505
September400510
October450515
November380520
December450530

Share Price Target 2030

Biocon wants to lead biopharmaceutical innovation worldwide by 2030. With a varied portfolio of biosimilars and new biologics, the business should be robust in key global markets. Their advanced research and development may lead to breakthrough medicines. Biocon’s sustainability and cheap healthcare solutions should appeal globally. For 2030, the price objective is ₹1000. Our study predicts a price range of ₹800 to ₹1000.

YearMinimum Price (₹)Maximum Price (₹)
20308001000
MonthMinimum Price (₹)Maximum Price (₹)
January800820
February820840
March840860
April860880
May880900
June900920
July920940
August940960
September960970
October970980
November980990
December9901000

Share Price Target 2050

Biocon is expected to dominate biotechnology and customized medicine by 2050. The company’s long-term investments in genomics, AI in drug development, and sophisticated therapeutics should pay off. Biocon’s dedication to healthcare innovation and accessibility may make it a worldwide health leader. The pricing objective for 2050 is ₹3000. Our study predicts a price range of ₹2200 to ₹3000.

YearMinimum Price (₹)Maximum Price (₹)
205022003000
MonthMinimum Price (₹)Maximum Price (₹)
January22002250
February22502300
March23002350
April23502400
May24002450
June24502500
July25002600
August26002700
September27002800
October28002850
November28502900
December29003000

Should I buy Biocon stock?

YearMinimum Price (₹)Maximum Price (₹)
2024250450
2025300530
20308001000
205022003000

Many variables must be considered before investing in Biocon stock. Positive signs include the company’s biosimilar market position, research and development emphasis, and worldwide growth strategy. Investors should also consider biopharmaceutical sector competitiveness and regulatory issues.

Recent quarterly results show Biocon’s strong financial performance, with net income rising significantly. The company’s product expansion and market entry are remarkable. Biocon may appeal to biotechnology investors with a lower P/E ratio of 27.68.

Biocon Industries Ltd Earning Results

Biocon’s latest financial results show outstanding performance and development prospects. In the June 2024 quarter, Biocon reported consolidated sales of ₹34.33 billion, a small year-over-year rise. The net income increased significantly to ₹6.60 billion, suggesting increased profitability.

MetricQ1 FY2025Q1 FY2024YoY Change
Revenue₹34.33B₹34.23B+0.30%
Net Income₹6.60B₹1.01B+550.59%
EPS₹5.31₹0.85+524.58%
EBITDA₹5.96B₹6.30B-5.39%

Expert Forecasts on the Future of Biocon Industries Ltd.

Industry analysts are enthusiastic about Biocon’s future. Analysts expect the company’s biosimilar and new biologic portfolio to fuel growth. Biocon’s worldwide growth, especially in developing countries, is welcomed.

Some analysts expect Biocon will gain from the increased need for inexpensive biopharmaceuticals, particularly in underdeveloped nations. They warn that regulatory clearances, price pressures, and rivalry from established pharmaceutical firms and biosimilar producers may affect the company’s business.

Is Biocon stock good to buy? (Bull case & Bear case)

Bull Case:

  • Strength in biosimilar market growth
  • New solid biologics and biosimilars pipeline
  • Strategic ties with global drugmakers
  • Entry into new markets, especially developing economies
  • Focus on high-growth therapies like diabetes and cancer

Bear Case:

  • Regulatory issues and product clearance delays
  • Biopharmaceutical rivalry is fierce.
  • Potential biosimilar pricing pressures
  • R&D and clinical trial risks
  • Currency fluctuations affect international operations

Conclusion

Biocon Industries Ltd. is a promising long-term biotechnology investment. The company’s excellent foundations, unique product pipeline, and strategic worldwide expansion equip it for growth. Our estimates suggest continuous price appreciation over the next several decades, but longer-term uncertainty increases.

Market variables may cause short-term volatility, but long-term investors may find Biocon appealing for portfolio growth. The company’s adaptability to market changes and investments in future technology may support continued success.

Before investing, you should study and assess your financial objectives and risk tolerance. The dynamic biopharmaceutical business requires diversification and portfolio evaluation to manage investment risks.

FAQs

Biocon develops and manufactures biosimilars, new biologics, and complicated small molecule APIs for diabetes, cancer, and immunology.

Biocon stock has exhibited stability and growth potential, fluctuating from ₹217.50 to ₹395.80 in the previous 52 weeks, indicating corporate performance and market sentiment.

Biosimilar expansion, market penetration, strategic alliances, and high-potential medicinal research and development fuel growth.

Biocon is a major Indian biopharmaceutical company with a competitive P/E ratio. Its emphasis on biosimilars and new biologics sets it apart.

Regulatory issues, biosimilar market rivalry, product approval delays, and pharmaceutical research and development uncertainty are significant hazards.

Similar Stocks